Skip to content

    BIOCRYST PHARMACEUTICALS (BCRX) stock price & financials

    View BCRX earnings calls

    Overview

    Price

    Market Cap

    Sector

    Rank

    Performance+15.3% 1Y

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly
    MetricQ3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Trend
    EarningsRevenue
    $117.08M
    $131.53M
    $145.53M
    $163.35M
    $159.40M
    +36.1%
    $406.56M
    +209.1%
    $156.41M
    +7.5%
    $218.25M
    +33.6%
    Strengthening
    Operating Profit
    $7.69M
    -$4.51M
    $21.23M
    $29.79M
    $29.59M
    +284.7%
    $260.38M
    -$701.60M
    -3405.2%
    $98.47M
    +230.6%
    Weakening
    Net Profit
    -$14.03M
    -$26.80M
    $32.0K
    $5.08M
    $12.90M
    $245.84M
    -$721.81M
    -2255762.5%
    $78.39M
    +1441.7%
    Weakening
    EPS
    $-0.07
    $0.00
    $0.02
    $0.06
    $-2.98
    $0.31
    +1450.0%
    Strengthening
    Other Income
    -$21.14M
    -$21.48M
    -$20.47M
    -$23.30M
    -$17.46M
    +17.4%
    -$12.37M
    +42.4%
    -$19.21M
    +6.2%
    -$18.99M
    +18.5%
    Strengthening
    Interest
    $24.83M
    $24.45M
    $23.49M
    $21.58M
    $19.66M
    -20.8%
    $14.13M
    -42.2%
    $19.78M
    -15.8%
    $21.71M
    +0.6%
    Weakening
    Depreciation
    Profit before Tax
    -$13.45M
    -$25.99M
    $758.0K
    $6.49M
    $12.13M
    $248.02M
    -$720.81M
    -95193.4%
    $79.47M
    +1125.3%
    Weakening
    MarginsOPM
    6.6%
    -3.4%
    14.6%
    18.2%
    18.6%
    +182.5%
    64.0%
    -448.6%
    -3174.4%
    45.1%
    +147.5%
    Weakening
    Tax
    -4.4%
    -3.1%
    95.8%
    21.6%
    -6.3%
    -45.4%
    0.9%
    -0.1%
    -100.1%
    1.4%
    -93.7%
    Weakening
    ReturnsROIC
    0.7%
    1.2%
    -0.0%
    -0.2%
    -0.6%
    -191.9%
    -11.5%
    -1017.5%
    33.6%
    -3.7%
    -1441.7%
    Weakening

    Balance Sheet

    Balance Sheet

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    AssetsCash & Equivalents$26.73M$114.17M$272.13M$504.39M$304.77M$110.64M$104.71M$89.74M$154.97M
    Short-Term Investments
    Total Current Assets$114.35M$164.34M$323.80M$566.14M$516.50M$495.97M$421.97M$404.35M$484.68M
    Net PP&E$9.13M$7.35M$7.11M$15.19M$12.86M$16.59M$15.84M$16.33M$9.06M
    Goodwill
    Intangibles
    Total Assets$146.84M$175.28M$334.71M$588.15M$550.00M$516.96M$490.42M$514.16M$557.85M
    LiabilitiesTotal Current Liabilities$69.48M$92.33M$105.65M$103.72M$105.51M$149.99M$160.38M$196.07M$208.85M
    Short-Term Debt
    Long-Term Debt$30.00M$0$119.73M$136.08M$231.62M$303.23M$314.87M$0$395.40M
    Long-Term Leases$3.87M$5.96M$4.03M$8.39M$7.92M$8.57M$10.60M
    Total Liabilities$97.61M$137.03M$353.98M$695.14M$844.60M$972.49M$966.35M$633.31M$1.01B
    EquityCommon Stock & APIC$1.10M$1.54M$1.77M$1.84M$1.88M$2.06M$2.08M$2.13M$2.55M
    Retained Earnings-$731.97M-$840.63M-$1.02B-$1.21B-$1.45B-$1.68B-$1.77B-$1.51B-$2.15B
    Total Equity$49.23M$38.25M-$19.26M-$106.99M-$294.60M-$455.53M-$475.93M-$119.15M-$454.29M
    HighlightsNet Cash / (Debt)

    Cash Flow

    Cash Flow

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    ActivitiesCash from Operating-$92.56M-$89.58M-$135.11M-$142.16M-$161.85M-$95.14M-$52.02M$347.37M$376.13M
    Cash from Investing$4.77M$77.93M-$6.86M$15.80M-$128.24M-$131.50M$52.59M-$13.69M-$448.71M
    Cash from Financing$62.50M$99.10M$300.59M$359.67M$88.03M$32.48M-$5.76M-$349.93M$124.63M
    SummaryCapital Expenditure-$366.0K-$343.0K-$514.0K-$2.38M-$1.35M-$2.17M-$1.12M-$2.47M-$2.76M
    Free Cash Flow-$92.93M-$89.93M-$135.62M-$144.54M-$163.20M-$97.31M-$53.14M$344.90M$373.38M
    FCF Margin-450.0%-184.1%-761.4%-92.0%-60.3%-29.4%-11.8%39.4%39.7%

    Ratios